Journal articles on the topic 'Migraines'
To see the other types of publications on this topic, follow the link: Migraines.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Migraines.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Yamanaka, Gaku, Soken Go, Shinichiro Morichi, Mika Takeshita, Natsumi Morishita, Shinji Suzuki, Takamatsu Tomoko, et al. "Clinical Features and Burden Scores in Japanese Pediatric Migraines With Brainstem Aura, Hemiplegic Migraine, and Retinal Migraine." Journal of Child Neurology 35, no. 10 (June 1, 2020): 667–73. http://dx.doi.org/10.1177/0883073820927840.
Full textAbstract:
Background: Migraines are a broad spectrum of disorders classified by the type of aura with some requiring attentive treatment. Vasoconstrictors, including triptans, should be avoided in the acute phase of migraines with brainstem aura, in hemiplegic migraine, and in retinal migraine. This study investigated the characteristics and burden of these migraines. Methods: Medical charts of 278 Japanese pediatric patients with migraines were retrospectively reviewed. Migraine burden of migraines with brainstem aura, hemiplegic migraines, and retinal migraine was assessed using the Headache Impact Test-6™ (HIT-6) and the Pediatric Migraine Disability Assessment scale (PedMIDAS). Results: Of 278 patients screened, 12 (4.3%) patients with migraines with brainstem aura (n = 5), hemiplegic migraines (n = 2), and retinal migraine (n = 5) were enrolled in the study. All patients had migraine with/without typical aura, whereas some patients had coexisting migraine with another type of headache (chronic tension-type headache in 3 patients, and 1 each with frequent episodic tension-type headache, headache owing to medication overuse, and chronic migraine). Migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients with coexisting headaches had higher HIT-6 or PedMIDAS scores, whereas migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients without coexisting headache did not show high HIT-6 or PedMIDAS scores. Conclusion: All migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients experienced migraine with or without typical aura, and some patients having other coexisting headaches also had high PedMIDAS and HIT-6 scores. PedMIDAS and HIT-6 should not be considered diagnostic indicators of migraines with brainstem aura, hemiplegic migraines, or retinal migraine. In clinical practice for headaches in children, careful history taking and proactive assessment of the aura are needed for accurate diagnosis of migraines with brainstem aura, hemiplegic migraines, and retinal migraine.
2
Yamanaka, Gaku, Shinji Suzuki, Natsumi Morishita, Mika Takeshita, Kanako Kanou, Tomoko Takamatsu, Shinichiro Morichi, et al. "Experimental and Clinical Evidence of the Effectiveness of Riboflavin on Migraines." Nutrients 13, no. 8 (July 29, 2021): 2612. http://dx.doi.org/10.3390/nu13082612.
Full textAbstract:
Riboflavin, a water-soluble member of the B-vitamin family, plays a vital role in producing energy in mitochondria and reducing inflammation and oxidative stress. Migraine pathogenesis includes neuroinflammation, oxidative stress, and mitochondrial dysfunction. Therefore, riboflavin is increasingly being recognized for its preventive effects on migraines. However, there is no concrete evidence supporting its use because the link between riboflavin and migraines and the underlying mechanisms remains obscure. This review explored the current experimental and clinical evidence of conditions involved in migraine pathogenesis and discussed the role of riboflavin in inhibiting these conditions. Experimental research has demonstrated elevated levels of various oxidative stress markers and pro-inflammatory cytokines in migraines, and riboflavin’s role in reducing these marker levels. Furthermore, clinical research in migraineurs showed increased marker levels and observed riboflavin’s effectiveness in reducing migraines. These findings suggest that inflammation and oxidative stress are associated with migraine pathogenesis, and riboflavin may have neuroprotective effects through its clinically useful anti-inflammatory and anti-oxidative stress properties. Riboflavin’s safety and efficacy suggests its usefulness in migraine prophylaxis; however, insufficient evidence necessitates further study.
3
Flynn, Niamh. "Psychological Considerations in the Etiology and Pathophysiology of Migraines." OBM Neurobiology 05, no. 02 (March 18, 2021): 1. http://dx.doi.org/10.21926/obm.neurobiol.2102092.
Full textAbstract:
Although studies to understand the pathogenesis of migraines are in progress, no theory has adequately explained the etiology and pathophysiology of migraines to date. This has affected the development of treatment strategies for migraineurs. Currently, the pharmacological treatment for migraines provides both acute and prophylactic options to patients based on a biomedical model of pain. However, patients’ adherence to oral migraine preventive medication (OMPM) is poor, and their persistence is even lower when they cycle through a variety of OMPMs [1]. Although our understanding of the pathophysiology of migraines within the context of the current biopsychosocial model of pain has advanced in recent years, there is a need to better understand the role of social and psychological factors in the pathophysiology of this debilitating disease, which would pave the way for the development and acceptance of more diverse and inclusive treatments. In this review, we provide an overview of the various theories that purport to explain the pathogenesis of the headache phase of migraines, examine the usefulness and shortcomings of these theories, and investigate how psychological considerations may help develop treatments to assist migraine sufferers in managing their headaches better.
4
Lee, Sang-Hwa, Jong-Ho Kim, Young-Suk Kwon, Jae-June Lee, and Jong-Hee Sohn. "Risk of Vestibulocochlear Disorders in Patients with Migraine or Non-Migraine Headache." Journal of Personalized Medicine 11, no. 12 (December 8, 2021): 1331. http://dx.doi.org/10.3390/jpm11121331.
Full textAbstract:
Headaches, especially migraines, have been associated with various vestibular symptoms and syndromes. Tinnitus and hearing loss have also been reported to be more prevalent among migraineurs. However, whether headaches, including migraine or non-migraine headaches (nMH), are associated with vestibular and cochlear disorders remains unclear. Thus, we sought to investigate possible associations between headache and vestibulocochlear disorders. We analyzed 10 years of data from the Smart Clinical Data Warehouse. In patients with migraines and nMH, meniere’s disease (MD), BPPV, vestibular neuronitis (VN) and cochlear disorders, such as sensorineural hearing loss (SNHL) and tinnitus, were collected and compared to clinical data from controls who had health check-ups without headache. Participants included 15,128 with migraines, 76,773 patients with nMH and controls were identified based on propensity score matching (PSM). After PSM, the odds ratios (OR) in subjects with migraine versus controls were 2.59 for MD, 2.05 for BPPV, 2.98 for VN, 1.74 for SNHL, and 1.97 for tinnitus, respectively (p < 0.001). The OR for MD (1.77), BPPV (1.73), VN (2.05), SNHL (1.40), and tinnitus (1.70) in patients with nMH was also high after matching (p < 0.001). Our findings suggest that migraines and nMH are associated with an increased risk of cochlear disorders in addition to vestibular disorders.
5
Adeney, KL, JL Flores, JC Perez, SE Sanchez, and MA Williams. "Prevalence and Correlates of Migraine Among Women Attending a Prenatal Care Clinic in Lima, Peru." Cephalalgia 26, no. 9 (September 2006): 1089–96. http://dx.doi.org/10.1111/j.1468-2982.2006.01171.x.
Full textAbstract:
Migraine headaches are among the leading causes of disability in the world. The burden of migraines is highest in women of reproductive age. This cross-sectional study characterized the prevalence, symptoms and correlates of migrainous headaches in 154 pregnant women attending a prenatal care clinic in Lima, Peru. Lifetime prevalence of migraine defined by modified IHS criteria was 9.1± (95± CI 4.6–13.6). When probable migraines were included, the lifetime prevalence of migraine in this population was 29.2± (95± CI 22.0–36.4). Migraine headaches were associated with a maternal history of headache, childhood carsickness, a diagnosis of allergies, and a high frequency of fatigue. Although headache-related disability was low in terms of missed work and recreation, high rates of headache pain and medicinal use reflect the true impact on this population.
6
Rodríguez-Almagro, Daniel, Alexander Achalandabaso-Ochoa, Esteban Obrero-Gaitán, María C. Osuna-Pérez, Alfonso Javier Ibáñez-Vera, and Rafael Lomas-Vega. "Sleep Alterations in Female College Students with Migraines." International Journal of Environmental Research and Public Health 17, no. 15 (July 29, 2020): 5456. http://dx.doi.org/10.3390/ijerph17155456.
Full textAbstract:
Background: Many factors are thought to potentially trigger migraines, among which sleep disturbances are one of the most frequently reported. Both sleep disorders and migraines affect more women than men. This study aims to analyze sleep alterations in young adult women with migraines and how they are related to the presence, frequency, intensity, and disability of migraines in this population. Methods: Fifty-one female university students with physician-diagnosed migraines and 55 healthy female university students completed surveys assessing demographic information and frequency, intensity, and disability of migraines and sleep quality variables. Results: No differences in sleep quality were found between migraine subjects and healthy women (p = 0.815), but women with migraines presented higher daytime somnolence (p = 0.010), greater sleep disruptions (p = 0.002), and decreased sleep adequacy (p = 0.019). The presence of a migraine was significantly related to daytime somnolence (p = 0.003) and sleep disruptions (p = 0.021). Migraine-related disability was associated with sleep disruptions (p = 0.002), snoring (p = 0.016), and a decreased quantity of sleep (p = 0.040). Migraine frequency was related to sleep disturbance (p = 0.003) and snoring (p < 0.001). The intensity of migraines was associated with sleep disruptions (p = 0.004). Conclusions: Our results suggest a relationship between migraines and sleep alterations.
7
Suzuki, Keisuke, Yasuyuki Okuma, Tomoyuki Uchiyama, Masayuki Miyamoto, Ryuji Sakakibara, Yasushi Shimo, Nobutaka Hattori, et al. "The prevalence, course and clinical correlates of migraine in Parkinson’s disease: A multicentre case-controlled study." Cephalalgia 38, no. 9 (October 26, 2017): 1535–44. http://dx.doi.org/10.1177/0333102417739302.
Full textAbstract:
Background Previous studies have reported a lower migraine prevalence in Parkinson’s disease (PD) patients and improvements in migraine headaches after PD onset, but the clinical association of migraines with PD is unclear. Methods We analysed headache and migraine prevalence and clinical correlates in 436 PD patients (mean age, 69.3 ± 7.8 years) and 401 age- and sex-matched controls (mean age, 69.2 ± 8.6 years) in a case-controlled, multicentre study. Migraines were diagnosed by a questionnaire developed according to the International Classification of Headache Disorders, second edition. We evaluated changes in headache intensity, frequency and severity over several years around the onset of PD among PD patients with headaches or migraines, and over the past several years among control subjects with headaches or migraines. Results PD patients had lower lifetime (9.6% vs. 18.0%) and 1-year (6.7% vs. 11.0%) migraine prevalences than controls. However, lifetime (38.5% vs. 38.9%) and 1-year (26.1% vs. 26.2%) headache prevalence did not differ between PD patients and controls. After adjusting for gender, timing of the evaluation of headache changes, and recall period, PD patients with headaches or migraines exhibited a pronounced reduction in the intensity, frequency and overall severity of their headaches and migraines after the onset of PD compared with controls with headaches or migraines. PD patients with migraines exhibited a higher rate of depression and higher Pittsburgh Sleep Quality Index and PD sleep scale-2 scores than those without headaches. Conclusion While overall headache and migraine severity reduced after PD onset, the presence of migraines was associated with sleep disturbances and depression in PD patients.
8
Fu, Xianguo, Jing Yang, Xiaoyang Wu, Qifang Lin, Yuli Zeng, Qiaoqing Xia, Luoyuan Cao, Baoying Huang, and Genbin Huang. "Association between PRDM16, MEF2D, TRPM8, LRP1 gene polymorphisms and migraine susceptibility in the She ethnic population in China." Clinical and Investigative Medicine 42, no. 1 (March 23, 2019): E21—E30. http://dx.doi.org/10.25011/cim.v42i1.32389.
Full textAbstract:
Background: The prevalence of migraines in the She population, a minority in China, is significantly higher than that in Han Chinese and other Asian populations. Two single nucleotide polymorphisms (SNPs) have been found to be associated with migraine susceptibility in the She population.
Purpose: This study investigated four SNPs, identified in genome-wide association studies, within migraine-susceptible loci in Han Chinese for their association with migraine susceptibility in the She population.
Methods: Two-hundred unrelated migraine patients and 200 healthy controls
were recruited. The SNPs examined included rs2651899 (PRDM16 ), rs2274316 (MEF2D ), rs7577262 (TRPM8) and rs11172113 (LRP1). Genotyping of the SNPs was performed by allele-specific polymerase chain reaction and direct sequencing.
Results: No significant differences between the participants with migraines and controls (participants without migraines) were demonstrated in genotypes, alleles and allele carriage frequencies for the four SNPs. A subgroup analysis found that migraine with aura had a lower frequency of C allele positivity in rs2651899 than in healthy controls (59.6% vs. 74.5%, respectively; P < 0.034). Univariate analyses indicated that no genotype of the four SNPs had a significant association with migraines. Males had a lower risk of migraines, and advanced age was a significant risk factor for migraines in females.
Conclusion: The SNPs in four migraine susceptible loci in Han Chinese were not risk factors for migraines in a relatively small sample of the She population.
9
Dima, Lorena, Andreea Bălan, Marius Alexandru Moga, Cătălina Georgeta Dinu, Oana Gabriela Dimienescu, Ioana Varga, and Andrea Elena Neculau. "Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines." Toxins 11, no. 8 (August 8, 2019): 465. http://dx.doi.org/10.3390/toxins11080465.
Full textAbstract:
Background: In 1989, Botulinum toxin (BoNT) was accepted by the FDA for the management of some ophthalmic disorders. Although it was initially considered a lethal toxin, in recent times, Botulinum toxin A (BoNT-A), which is the more used serotype, has expanded to cover different clinical conditions, primarily characterized by neuropathic pain, including migraines and headaches. Evidence suggests that migraines are influenced by hormonal factors, particularly by estrogen levels, but very few studies have investigated the prevalence and management strategies for migraines according to the hormonal status. The effects of several therapeutic regimens on migraines have been investigated, but the medications used varied widely in proven efficacies and mechanisms of action. BoNT-A is increasingly used in the management of migraine and several placebo-controlled trials of episodic and chronic migraine are currently underway. This paper is a review of the recently published data concerning the administration of BoNT-A in the prevention of chronic migraines. Considering the lack of population-based studies about the effectiveness of BoNT-A in the alleviation of premenstrual and perimenopausal migraines, this study proposes a new perspective of the therapeutic approach of migraine syndrome associated with menopausal transition and the premenstrual period. Methods: We selected the reviewed papers from CrossRef, PubMed, Medline, and GoogleScholar, and a total of 21 studies met our inclusion criteria. Results: To date, no specific preventive measures have been recommended for menopausal women with migraines. BoNT-A often reduces the frequency and intensity of migraine attacks per month; the treatment is well tolerated and does not exhibit a significantly higher rate of treatment-related side effects. No population-based studies were conducted in order to highlight the role of BoNT-A in menopause-related migraines, neither in menstrual migraines. Conclusion: There is a need for further research in order to quantify the real burden of menstrual and perimenopausal migraines and to clarify if BoNT-A could be used in the treatment of refractory postmenopausal and premenstrual migraines.
10
Simic, Svetlana, Petar Slankamenac, Milan Cvijanovic, Sofija Banic-Horvat, Zita Jovin, and Miroslav Ilin. "Menstrual migraine." Medical review 60, no. 9-10 (2007): 449–52. http://dx.doi.org/10.2298/mpns0710449s.
Full textAbstract:
Introduction. The prevalence of migraine in childhood and adolescence has not changed to a great extent, but it increases in adolescence, especially in female adolescents. Menstrual migraine ? definition. There are two types of menstrual migraine: true menstrual migraine and menstrual related migraine. True menstrual migraine occurs predominantly around menstruation, whereas menstrual related migraine occurs during menstruation, but also at other times during the month. Causes. Exaggerated or abnormal neurotransmitter responses to normal cyclic changes in the ovarian hormones are probably the basic cause of menstrual migraines. The fall in estrogen levels during menstrual cycle is trigger for the menstrual migraine. Symptoms. Menstrual migraine has the same symptoms as other types of migraine, but the pain is stronger, IT lasts longer, AND IT IS more frequent than other types of migraines. Diagnosis. In order to make a diagnosis, women are asked to keep a headache diary for three months. If the migraine headache is severe and occurs regularly between two days before and three days after the start of menstrual bleeding, it is true menstrual migraine. Therapy. Menstrual migraines are more difficult to treat than other types of migraines. Treatment principles for menstrual migraine are the same as for migraines in general, with certain particularities. Conclusion. Hormonally associated migraine is a specific clinical entity. It is important to diagnose the type of migraine, considering the fact that a decline in estrogen level at the end of menstrual cycle triggers migraine, so it can be treated by low levels of estrogen. .
11
Allais, Gianni, Margarita Sanchez del Rio, Hans-Christoph Diener, Chiara Benedetto, Joop Pfeil, Barbara Schäuble, and Joop van Oene. "Perimenstrual migraines and their response to preventive therapy with topiramate." Cephalalgia 31, no. 2 (July 22, 2010): 152–60. http://dx.doi.org/10.1177/0333102410378049.
Full textAbstract:
Introduction: Preventive treatment with topiramate is effective for overall reduction of migraine frequency, but there are few data regarding its efficacy on perimenstrual migraines. To determine whether topiramate can prevent perimenstrual migraines, we analyzed data from premenopausal women as a subgroup of the Prolonged Migraine Prevention with Topiramate (PROMPT) study. Methods: In total, 198 women from the PROMPT study with menstrually related migraine (MRM) were evaluated. After a one-to-two–month prospective baseline period, patients received open-label topiramate (50–200 mg/day) for six months. Results: During topiramate treatment, mean monthly migraine frequency was reduced from 7.03 at baseline to 4.36 (mean change: −2.66; p < .001, endpoint analysis). Mean percentage reductions were similar for migraines during and outside the perimenstrual period (−45.9% and −46.1%, respectively). In patients with aura, reductions in migraine days with (−48.3%) or without (−43.4%) aura were similar to those in patients without aura (−45.4%). Reductions were also similar whether women were taking combined oral contraceptives (−47.0%) or were not (−46.6%). Conclusions: Topiramate reduces the frequency, but not severity or duration, of perimenstrual migraines in women with MRM, including migraines with and without aura, and regardless of combined oral contraceptive use.
12
Reuter, U., MS Del Rio, H.-C. Diener, G. Allais, B. Davies, A. Gendolla, J. Pfeil, S. Schwalen, B. Schäuble, and J. van Oene. "Migraines with and without aura and their response to preventive therapy with topiramate." Cephalalgia 30, no. 5 (October 1, 2009): 543–51. http://dx.doi.org/10.1111/j.1468-2982.2009.01999.x.
Full textAbstract:
Data from the Prolonged Migraine Prevention (PROMPT) with Topiramate trial were evaluated post hoc to determine whether topiramate could prevent migraine auras, and whether its efficacy in preventing migraine headaches was similar in patients with (MA; n = 269) and without (MoA; n = 542) aura. Migraines and auras were recorded during prospective baseline, 6-month open-label (OL) topiramate and 6-month double-blind (DB), placebo-controlled phases. In the last 28 OL days, migraines without aura and migraine auras decreased by 43.1% and 54.1%, respectively, in MA patients. MoA patients experienced a 44.3% reduction in migraines. In the DB phase, increases in migraines with placebo vs. topiramate were similar to the full study, but were generally not statistically significant, probably due to lack of power in the subgroup analysis. Similarly, there were no statistically significant changes in number of auras between groups. Thus, topiramate appears to reduce migraine auras in parallel with headache reductions, which are similar in patients with and without aura.
13
Wong, Cheryl M., and Eric Hollander. "Serotonin Function and Gender Effects in Migraine Production and OCD." CNS Spectrums 2, no. 2 (February 1997): 25–27. http://dx.doi.org/10.1017/s1092852900001760.
Full textAbstract:
AbstractA high prevalence of comorbidity has been reported between migraines and psychiatric disorders. It has been proposed that migraine headaches are mediated by stimulation of serotonin (5-HT) receptors. Past studies have demonstrated that migraine-like headaches have been produced following administration of the partial 5-HT agonist m-chlorophenylpiperazine (m-CPP; believed to primarily affect the 5-HT2C receptor) in patients with migraines or eating disorders, especially bulimia, as well as in normal controls. We review the association between 5-HT dysfunction, as determined by response to m-CPP challenge, and migraines, looking specifically at the relationship between migraines and obsessive-compulsive disorder and gender effects.
14
Liao, Chung-Chih, Chi-Hsien Chien, Ying-Hsiu Shih, Fuu-Jen Tsai, and Jung-Miao Li. "Acupuncture Is Effective at Reducing the Risk of Stroke in Patients with Migraines: A Real-World, Large-Scale Cohort Study with 19-Years of Follow-Up." International Journal of Environmental Research and Public Health 20, no. 3 (January 17, 2023): 1690. http://dx.doi.org/10.3390/ijerph20031690.
Full textAbstract:
Migraines are common headache disorders and risk factors for subsequent strokes. Acupuncture has been widely used in the treatment of migraines; however, few studies have examined whether its use reduces the risk of strokes in migraineurs. This study explored the long-term effects of acupuncture treatment on stroke risk in migraineurs using national real-world data. We collected new migraine patients from the Taiwan National Health Insurance Research Database (NHIRD) from 1 January 2000 to 31 December 2017. Using 1:1 propensity-score matching, we assigned patients to either an acupuncture or non-acupuncture cohort and followed up until the end of 2018. The incidence of stroke in the two cohorts was compared using the Cox proportional hazards regression analysis. Each cohort was composed of 1354 newly diagnosed migraineurs with similar baseline characteristics. Compared with the non-acupuncture cohort, the acupuncture cohort had a significantly reduced risk of stroke (adjusted hazard ratio, 0.4; 95% confidence interval, 0.35–0.46). The Kaplan–Meier model showed a significantly lower cumulative incidence of stroke in migraine patients who received acupuncture during the 19-year follow-up (log-rank test, p < 0.001). Acupuncture confers protective benefits on migraineurs by reducing the risk of stroke. Our results provide new insights for clinicians and public health experts.
15
Sun, Juan. "Migraines in medical students from Inner Mongolia University." Pacific International Journal 5, no. 3 (October 1, 2022): 65–77. http://dx.doi.org/10.55014/pij.v5i3.201.
Full textAbstract:
Aims: This study aimed to evaluate the prevalence of migraines and related factors.
Methods: The survey employed was a self-administered questionnaire regarding various migraine symptoms and related factors administered to medical students attending Inner Mongolia Medical College in China. We calculate migraine prevalence and evaluate migraine-related factors. Migraine prevalence based on related factors and according to gender were compared using χ2 tests. The proportion of other symptoms related to migraines was also calculated.
Results: 17.2% of surveyed students had experienced migraines. The migraines prevalence among students who used the computer for over three hours was nearly 1.5 times higher than for those who used it for less than one hour. Of those students who used a computer for more than 3 hours, migraine prevalence among female students was approximately 1.5 times greater than for males. The migraine prevalence among students with poor sleep was nearly two times higher than among those with good sleep. The migraine prevalence among students with anxiety was approximately 2.5 times higher relative to those who experienced no anxiety. The most common symptom complaint associated with migraines (>97%) included limited ability to study and restricted daily activities.
Conclusions: Although the migraine prevalence in our study was moderate, it led to serious limitations in students’ study time and daily activities. In addition to measures to relieve anxiety and improve sleep quality, stricter control of computer use will be necessary, especially in female. Taken together, our study provides better insight regarding medical students’ migraine-related problems.
16
Baker, Virginia, and Nawaz Hack. "Improving access to care for patients with migraine in a remote Pacific population." Neurology: Clinical Practice 10, no. 5 (November 25, 2019): 444–48. http://dx.doi.org/10.1212/cpj.0000000000000774.
Full textAbstract:
ObjectiveTo evaluate the efficacy of increasing access to care for patients with migraines in a rural setting. Outcomes include decreased resource utilization, decreased hospitalizations, polypharmacy reduction, and decreased disability in a remote Pacific population.MethodsData were collected on all patients presenting to a single neurologist in a deployed military setting for migraines. Access to care was supplemented through health fairs, radio shows, telemedicine, and education of primary care providers.ResultsOver the course of 1 year, 300 providers were educated through public health fairs and telemedicine counseling. This strategy helped reduce consults by 50% and decrease clinic wait times from 2 months to 7 days. Two hundred twenty-one patients with chronic migraine or episodic migraine were seen in the neurology clinic over the course of 1 year. Of these patients, polypharmacy reduction was achieved in 71% of patients with chronic migraines and in 44% of patients with episodic migraines. Over the course of 1 year, only 13% of patients with chronic migraines and 11% of patients with episodic migraines were treated in an acute care setting. Less than 2% of patients had limitations in their work duties because of migraines.ConclusionIncreased access to care provided benefits in reduction of specialist overutilization, reduction in hospitalizations, and reduction in disability. Patients with chronic migraine did not have increased use of medical resources or decreased productivity in this cohort.
17
Chen, Chien-Hua, Cheng-Li Lin, and Chia-Hung Kao. "Gallbladder Stone Disease Is Associated with an Increased Risk of Migraines." Journal of Clinical Medicine 7, no. 11 (November 21, 2018): 455. http://dx.doi.org/10.3390/jcm7110455.
Full textAbstract:
Background: Several pathophysiological mechanisms are shared in both gallbladder stone disease (GSD) and migraines. We assessed the migraine risk for patients diagnosed with GSD. Methods: We identified 20,427 patients who were diagnosed with GSD between 2000 and 2011 from Taiwan’s National Health Insurance Research Database (NHIRD) as the study cohort. We randomly selected 81,706 controls from the non-GSD population with frequency matching by age and index year for the control cohort. All patient cases were followed until the end of 2011 to measure the incidence of migraines. Results: The cumulative incidence of migraines was greater in patients with GSD than in those without GSD (log-rank test: p < 0.001). The risk of migraine (3.89 vs. 2.30 per 10,000 person-years, adjusted hazard ratio (aHR) = 1.56, 95% confidence interval (CI) = 1.41–1.73) was greater for the GSD cohort than that for the non-GSD cohort. The risk of migraine increased with the time of follow-up after a diagnosis of GSD. The risk of migraine contributed by GSD was greater for all age groups. The risk of migraine for GSD patients with depression (aHR = 2.89, 95% CI = 2.21–3.77), anxiety (aHR = 2.07, 95% CI = 1.58–2.70), and coronary artery disease (CAD) (aHR = 2.05, 95% CI = 1.69–2.48) tended to be greater than that for GSD patients without depression (aHR = 1.54, 95% CI = 1.39–1.72), anxiety (aHR = 1.62, 95% CI = 1.46–1.81), and CAD (aHR = 1.65, 95% CI = 1.47–1.85), respectively. Compared with the patients without GSD, the risk of developing migraines was greater in those GSD patients either with (aHR = 1.39, 95% CI = 1.19–1.63) or without (aHR = 1.67, 95% CI = 1.48–1.88) cholecystectomy. Compared with the GSD patients that have not had a cholecystectomy, the risk of developing migraines was lower in the GSD patients that had a cholecystectomy (aHR = 0.83, 95% CI = 0.69–0.99). Conclusions: GSD is associated with an increased risk of migraines in the Taiwanese population, but the risk diminishes after a cholecystectomy. Furthermore, in the development of migraines, GSD is synergic with some migraine-associated comorbidities, such as CAD, depression, and anxiety. Further study is necessary to clarify whether GSD is a causal risk factor for migraine.
18
Dai, Lingling, Qiang Xu, Xing Xiong, Yang Yu, Ximing Wang, Hui Dai, Hongru Zhao, and Jun Ke. "Propagation Structure of Intrinsic Brain Activity in Migraine without Aura." Brain Sciences 12, no. 7 (July 10, 2022): 903. http://dx.doi.org/10.3390/brainsci12070903.
Full textAbstract:
Previous studies have revealed highly reproducible patterns of temporally lagged brain activity in healthy human adults. However, it is unknown whether temporal organization of intrinsic activity is altered in migraines or if it relates to migraine chronification. In this resting-state functional magnetic resonance imaging study, temporal features of intrinsic activity were investigated using resting-state lag analysis, and 39 episodic migraine patients, 17 chronic migraine patients, and 35 healthy controls were assessed. Temporally earlier intrinsic activity in the hippocampal complex was revealed in the chronic migraine group relative to the other two groups. We also found earlier intrinsic activity in the medial prefrontal cortex in chronic compared with episodic migraines. Both migraine groups showed earlier intrinsic activity in the lateral temporal cortex and sensorimotor cortex compared with the healthy control group. Across all patients, headache frequency negatively correlated with temporal lag of the medial prefrontal cortex and hippocampal complex. Disrupted propagation of intrinsic activity in regions involved in sensory, cognitive and affective processing of pain may contribute to abnormal brain function during migraines. Decreased time latency in the lateral temporal cortex and sensorimotor cortex may be common manifestations in episodic and chronic migraines. The temporal features of the medial prefrontal cortex and hippocampal complex were associated with migraine chronification.
19
Fila, Michal, Cezary Chojnacki, Jan Chojnacki, and Janusz Blasiak. "Is an “Epigenetic Diet” for Migraines Justified? The Case of Folate and DNA Methylation." Nutrients 11, no. 11 (November 14, 2019): 2763. http://dx.doi.org/10.3390/nu11112763.
Full textAbstract:
Migraines are a common disease with limited treatment options and some dietary factors are recognized to trigger headaches. Although migraine pathogenesis is not completely known, aberrant DNA methylation has been reported to be associated with its occurrence. Folate, an essential micronutrient involved in one-carbon metabolism and DNA methylation, was shown to have beneficial effects on migraines. Moreover, the variability of the methylenetetrahydrofolate reductase gene, important in both folate metabolism and migraine pathogenesis, modulates the beneficial effects of folate for migraines. Therefore, migraine could be targeted by a folate-rich, DNA methylation-directed diet, but there are no data showing that beneficial effects of folate consumption result from its epigenetic action. Furthermore, contrary to epigenetic drugs, epigenetic diets contain many compounds, some yet unidentified, with poorly known or completely unknown potential to interfere with the epigenetic action of the main dietary components. The application of epigenetic diets for migraines and other diseases requires its personalization to the epigenetic profile of a patient, which is largely unknown. Results obtained so far do not warrant the recommendation of any epigenetic diet as effective in migraine prevention and therapy. Further studies including a folate-rich diet fortified with valproic acid, another modifier of epigenetic profile effective in migraine prophylaxis, may help to clarify this issue.
20
Im, Hee-Ji, and Soo-Jin Cho. "Pharmacotherapy of migraine prevention based on the assessment of headache." Journal of the Korean Medical Association 63, no. 10 (October 10, 2020): 644–49. http://dx.doi.org/10.5124/jkma.2020.63.10.644.
Full textAbstract:
Migraine as a recurrent, relapsing, and chronic disease is one of the most disabling disorders globally. Most patients are women in their reproductive age and their migraines are classified as episodic migraine. Although less than half of the episodic and most chronic migraineurs require preventive intervention, early discontinuation rates are high, owing to poor tolerability and insufficient awareness about migraine. This article aims to review the recent update of migraine prevention based on the practice guidelines for the prevention of episodic migraine published by the Korea Headache Society and the position statement of the American Headache Society in 2019. The goal of migraine prevention is to reduce migraine attack frequency by at least 50 %, the number of migraine days, and the attack severity to ultimately improve quality of life. The guidelines recommend considering the initiation of preventive medication when recurring migraines significantly interfere with daily life or when acute treatment is contraindicated or inappropriate. Preventive medications should be determined based on various qualified assessments. Pharmacologic treatments are recommended for migraine prophylaxis include antidepressant (amitriptyline), anti-epileptic drugs (topiramate, divalproex sodium), beta-blockers (propranolol, metoprolol), calcium channel blocker (flunarizine), and intramuscular injection of onabotulinumtoxin A. Furthermore subcutaneous or intravenous injection of calcitonin gene-related peptide monoclonal antibodies was recently approved as a new therapy for migraine prevention. Migraine is a chronic debilitating disorder. The initiation of evidence-based preventive management is necessary and management methods should be individually selected to improve quality of life.
21
Thiagarajan, Anuradha, Noor Azah Aziz, Chai-Eng Tan, and Noor Azimah Muhammad. "The profile of headaches and migraine amongst medical students and its association to stress level, disability and self-management practices." Malaysian Family Physician 17, no. 2 (May 25, 2022): 81–88. http://dx.doi.org/10.51866/oa1370.
Full textAbstract:
Introduction: Migraine is the most common headache affecting young people that impairs their functional ability. This study aimed to determine the frequency of migraines among Malaysian medical students, the association between migraines, stress level, and functional disability among these students, and describe their self-management practices. Methods: A cross-sectional study was conducted among medical students in a private medical school in Penang state. All medical students in the study site were screened for the presence of headache symptoms and the diagnosis of migraine using a self-administered questionnaire comprising International Headache Society (IHS) diagnostic criteria. Other domains that were assessed were perceived stress level and functional disability, which were measured using the Perceived Stress Scale and the Headache Impact Test-6 (HIT-6), respectively. The students’ self-management practices for their headaches were determined using a descriptive survey. Results: A total of 374 medical students participated in this study and 157 (42%) students reported experiencing headaches. More than half (n=97, 61.8%) of those with headaches fulfilled the IHS criteria for migraines. Migraines were significantly associated with functional disability compared with non-migraine headaches (p<0.001); however, no significant difference in stress levels were reported between the two groups. During migraine attacks, sleep (n=73, 60.33%) and self-medication (n=56, 69.14%) were the most common self-management practices. Only 11.46% of the 157 students with headaches consulted a doctor. Conclusion: A high proportion of medical students suffered from headaches and more than half of them had migraines. Migraine headaches were associated with significant functional disability. Very few students sought medical consultation and most students chose to self-manage their headaches.
22
Terry, D. P., A. J. Gardner, and G. L. Iverson. "Systematic Review of Pre-Injury Migraine Disorder as a Risk Factor for Worse Outcome Following Sport-Related Concussion." Archives of Clinical Neuropsychology 34, no. 5 (July 2019): 754. http://dx.doi.org/10.1093/arclin/acz026.24.
Full textAbstract:
Abstract Purpose This systematic review examined clinical outcomes (i.e., prognosis) following a sport-related concussion in athletes who have a pre-injury history of migraines. Clinical recovery was defined functionally as recovery from symptoms or full return to activities following injury. Data Selection All studies published prior to February 2019 that addressed pre-injury migraines as a possible predictor of clinical recovery from concussion were included. Broadly, the search included (i) sport/athlete-related terms, (ii) concussion-related terms, and (iii) diverse predictor/modifier terms. The following databases were utilized: PubMed, PsycINFO®, MEDLINE®, CINAHL, Cochrane Library, EMBASE, SPORTDiscus, Scopus, and Web of Science. After removing duplicates from the 9,372 identified articles, 5,888 abstracts were screened, 358 full-text articles were reviewed, and 15 articles examining pre-injury migraines as a predictor of recovery were included. Data Synthesis Most articles examined pre-injury migraines as an exploratory/secondary predictor of concussion outcome. Migraine history was predominantly based on self-report. Studies included minimal other information about this condition (e.g., age of onset, migraine frequency/severity, past treatment). Methodological rigor varied greatly across studies. Most studies did not find pre-injury migraines to be associated with concussion outcome, but several of these studies had small or very small sample sizes. Larger, better-designed studies suggested pre-injury migraines may be a risk factor for worse concussion outcome. Effect sizes were rarely reported or able to be calculated. Conclusion There is some evidence to suggest pre-injury migraines may be a vulnerability factor for a prolonged recovery following concussion. Future studies should focus on improving methodological quality when assessing the relationship between pre-injury migraines and concussion outcome.
23
Latysheva, N. V., E. G. Filatova, and N. V. Naprienko. "Treatment of migraines during pregnancy." Russian Medical Inquiry 4, no. 9 (2020): 601–5. http://dx.doi.org/10.32364/2587-6821-2020-4-9-601-605.
Full textAbstract:
One in four women of reproductive age suffers from migraines with varying incidence of episodes. Treatment of migraines during pregnancy is a complex problem for doctors and patients. Nowadays, more than 70% of pregnant women receive prescription and overthe- counter medications during pregnancy. At the same time, information about the safety of taking such drugs by pregnant women is commonly not available. That is why doctors and patients use certain medications without a premeditated and coordinated tactics for controlling migraines, commonly making a decision at the beginning of the next episode. The article provides detailed information about the course patterns, as well as the rules for managing migraines during pregnancy. The article also describes the recommendations for developing an optimal tactics for relieving seizures and preventive therapy. Following these recommendations will allow patients to adequately prepare for pregnancy, avoid taking unsafe medications, while maintaining optimal control over the incidence and duration of migraine episodes during this critical perio d. KEYWORDS: migraine, pregnancy, seizure prevention, preventive treatment, sumatriptan, neurostimulation. FOR CITATION: Latysheva N.V., Filatova E.G., Naprienko N.V. Treatment of migraines during pregnancy. Russian Medical Inquiry. 2020;4(9):601–605. DOI: 10.32364/2587-6821-2020-4-9-601-605.
24
Gross, Elena C., Rainer J. Klement, Jean Schoenen, Dominic P. D’Agostino, and Dirk Fischer. "Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention." Nutrients 11, no. 4 (April 10, 2019): 811. http://dx.doi.org/10.3390/nu11040811.
Full textAbstract:
An increasing amount of evidence suggests that migraines are a response to a cerebral energy deficiency or oxidative stress levels that exceed antioxidant capacity. The ketogenic diet (KD), a diet mimicking fasting that leads to the elevation of ketone bodies (KBs), is a therapeutic intervention targeting cerebral metabolism that has recently shown great promise in the prevention of migraines. KBs are an alternative fuel source for the brain, and are thus likely able to circumvent some of the abnormalities in glucose metabolism and transport found in migraines. Recent research has shown that KBs—D-β-hydroxybutyrate in particular—are more than metabolites. As signalling molecules, they have the potential to positively influence other pathways commonly believed to be part of migraine pathophysiology, namely: mitochondrial functioning, oxidative stress, cerebral excitability, inflammation and the gut microbiome. This review will describe the mechanisms by which the presence of KBs, D-BHB in particular, could influence those migraine pathophysiological mechanisms. To this end, common abnormalities in migraines are summarised with a particular focus on clinical data, including phenotypic, biochemical, genetic and therapeutic studies. Experimental animal data will be discussed to elaborate on the potential therapeutic mechanisms of elevated KBs in migraine pathophysiology, with a particular focus on the actions of D-BHB. In complex diseases such as migraines, a therapy that can target multiple possible pathogenic pathways seems advantageous. Further research is needed to establish whether the absence/restriction of dietary carbohydrates, the presence of KBs, or both, are of primary importance for the migraine protective effects of the KD.
25
Zeigler, Zella Rose, and Andrea L. Cortese Hassett. "Thrombophilic Patients with Migraines Have a High Incidence of Antiphospholipid Antibodies." Blood 106, no. 11 (November 16, 2005): 4133. http://dx.doi.org/10.1182/blood.v106.11.4133.4133.
Full textAbstract:
Abstract Migraines are associated with an increased risk of stroke and are recognized as a non-stroke neurologic complicaton in the antiphospholipid syndrome (aPls). Traditional tests for antiphospholipid antibodies (APA) include PTT assays [aPTT, dRVV, and Hexagonal phospholipid (Hex PL)], a dilute PT assay (Tissue Thromboplastin Inhibition) for lupus anticoagulants (LAC), and ELISA assays for anticardiolipin antibodies (ACA). These assays have not correlated with migraines. It is now recognized that antibodies to a phospholipid binding protein called beta-2-GPI are important in autoimmune aPls. Some patients (pts) with aPls are sero-negative, eg. negative in the routine assays, but have + anti-beta-2-GPI antibodies. Animal studies have shown an association of the latter antibodies to neurologic dysfunction. This study is a clinical retrospective medical record methodology, examining the relationship between migraines and APA results in pts referred to the Hemostasis & Thrombosis Clinic at the Institute for Transfusion Medicine from 7/1/03-7/15/05. Inclusion criteria were any pt. referred to the PI, who had a LAC screening panel and anti-beta-2-GPI testing. Exclusion criteria were any pt who did not have this testing or were + without repeat testing >2 mos later. Abstracted data included history of migraines (with or without aura), opthalmic migraines, referral reason, age, sex and APA results. Results were considered to be + (in non-anticoagulated pts), if any of the clotting assays were repeatedly +, did not correct on a mix, and shortened with phospholipid. Patients with only a + clotting assay, were taken off coumadin (OAC) and retested. Patients with + ELISA assays on OAC Rx, required an abnormal dRVV mix and/or a + Hex PL assay to be considered as + for a LAC. ELISA results were considered as +, if they were low titer or higher, e.g. ≥ mean ± 3 SD. The cohort consisted of 258 pts (69M: 189F) with a median age of 48 (range=13–85). Of these, 76 (29%) had migraines. Thirty-five/258 (13.6%) of the pts were referred for risk assessment and 10/35 (28.6%) had migraines. The remaining 223 pts were referred for clinical events: arterial or venous thrombosis [n= 133/233 (59.6%)], neurologic reasons [n=62/223 (28.2%)] and other [n=27/233 (12.1%)]. Of this group, migraines were present in 66 (29.6%). None of the 10 risk pts with migraines had + results. One of the 25 risk pts had a + anti-beta-2-GPI antibody (1/25=4.0%). Positive APA were detected in 58/233 (24.9%) pts with clinical events. Table 1 is a breakdown of the APA results vs migraines in pts with events vs those evaluated for risk issues. It appears that pts with thrombotic events with migraines have a higher incidence of +APA than those who do not have migraines. This data supports the suspected association between migraines and APA in the thrombphilic pt population. The same does not appear to be true in pts (without a thrombotic event) undergoing risk assessment. Incidence of Positive APA in Patients with regard to Migraine Status Group Total Pos Total Neg P OR CI APA = LAC/ACA and/or anti-beta-2-GPI Risk-no migraine 1/25 (4%) 24/25 (96%) Risk-migraines 0/10 (0%) 10/10 (100%) 1.00 0.810 0.03–21.5 Events-ALL pts 58/233 (25%) 175/233 (75%) 0.002 11.27 1.51 to 84.2 Events-no migraine 30/157 (19%) 127/157 (81%) 0.058 5.83 0.77 to 44.22 Events-migraines 28/66 (42%) 38/66 (58%) <0.001 25.05 3.23 to 194.2
26
Edinoff, Amber N., C. Austin Casey, Marc A. Colon, Alexa R. Zaheri, Courtney M. Gregoire, Margaret M. Bourg, Alan D. Kaye, et al. "Ubrogepant to Treat Acute Migraine in Adults." Neurology International 13, no. 1 (January 28, 2021): 32–45. http://dx.doi.org/10.3390/neurolint13010004.
Full textAbstract:
Migraine is a neurobiological headache disorder that affects around 16% of adults in the United States. Medical treatment of mild to moderate migraines include non-prescription non-steroidal anti-inflammatory drugs, acetaminophen, or aspirin and caffeine-containing combination analgesics. Additionally, moderate to severe migraines and those that are mild to moderate that have not responded to analgesics can be treated with triptans, which are drugs specific for migraine treatment. Non-pharmacological treatments include cognitive behavioral therapy and relaxation training. Medications for the prevention of migraines have also been developed since they are more affective in offsetting the symptoms. Ubrogepant’s high specificity and selectivity for calcitonin gene-related peptide (CGRP) sets it apart from certain other drugs, which previously limited the treatment of migraines with or without aura due to their decreased selectivity. The most frequently reported side effects are oropharyngeal pain, nasopharyngitis, and headache. Most studies found that participants receiving Ubrogepant were free from pain within 2 h when compared to placebo. Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease. In summary, Ubrogepant has good tolerability and an overall favorable safety profile. It appears to hold promise for the acute treatment of migraines with or without aura in adults.
27
Lui, Jacob Z., Nathan P. Young, Jon O. Ebbert, Jordan K. Rosedahl, and Lindsey M. Philpot. "Loneliness and Migraine Self-Management: A Cross-Sectional Assessment." Journal of Primary Care & Community Health 11 (January 2020): 215013272092487. http://dx.doi.org/10.1177/2150132720924874.
Full textAbstract:
Background: Chronic illness is often comorbid with the psychological state of loneliness. Models of care for patients who experience chronic migraines may often lack an understanding of psychosocial influences of the illness. Addressing the effects of loneliness on the health behaviors of chronic migraine patients may further elucidate gaps in care that exist beyond the biomedical approach to migraine treatment. The primary aim of this study was to assess the relationship between loneliness and behavioral health decisions in chronic migraine patients, specifically patient ability to self-manage, and effectiveness of treatments. Methods: We conducted a cross-sectional survey among patients (n = 500) with migraine and assessed for the experience of loneliness by using the University of California, Los Angeles–Revised (UCLA-R) Three-item Loneliness Scale and the extent of migraine-related disability via the Migraine Disability Assessment (MIDAS). Furthermore, we evaluated patients for their ability to self-manage their migraines, and perceived effectiveness of treatment. Results: Nearly half of our population reported at least one measure of loneliness (230/500, 46.0%). Patients experiencing chronic migraine were statistically more likely to report feeling lonely when compared to patients with episodic migraines ( P < .001). Patients who report loneliness had lower odds of feeling ’very satisfied” with their ability to self-manage their migraine symptoms (aOR = 0.34, 95% CI 0.14-0.81) and had lower odds of feeling “very satisfied” with their ability to avoid conditions that cause their headache (aOR = 0.39, 95% CI 0.16-0.91). Conclusions: Loneliness has significant effects on the illness experience of patients with chronic migraines, including their ability to self-manage or be satisfied with their current state of care. Psychosocial models of care that address loneliness among patients with chronic migraine may help improve health outcomes and management.
28
Susanti, Restu, and Syamel Muhammad. "Menstrual Migraine : How Hormones Impact Migraine." Journal Obgin Emas 5, no. 1 (January 18, 2021): 9–17. http://dx.doi.org/10.25077/aoj.5.1.9-17.2021.
Full textAbstract:
Menstrual Migraine is divided into 2 subtypes: Menstrually Related Migraine (MRM) and Pure Menstrual Migraines (PMM). In PMM symptoms do not occur outside the menstrual cycle while MRM, symptoms can occur at other times apart from the menstrual cycle. The occurrence of menstrual migraines is related to the female hormones cycle in the form of the decrease in estrogen levels which usually occurs a week before the onset of menstruation. The mechanism is unclear, but it is thought that a decrease in estrogen levels can trigger decrease in serotonin levels, causing cranial vasodilation and sensitization of the trigeminal nerve. Keywords: menstrual migraine, hormones
29
Ostashko, M. P., and T. I. Nasonova. "MARKERS OF NEUROVISULATION IN MIGRAINE DIAGNOSTICS." PRECARPATHIAN BULLETIN OF THE SHEVCHENKO SCIENTIFIC SOCIETY Pulse, no. 5(57) (April 24, 2019): 108–13. http://dx.doi.org/10.21802/10.21802/2304-7437-2019-5(57)-108-113.
Full textAbstract:
In clinical medicine, the diagnosis of migraine is based on anamnesis and symptoms, and instrumental diagnostic methods are considered non-informative. Numerous studies of the brain, during headaches and between them, have made a significant contribution to understanding the pathophysiology of migraines. Structural and functional changes in the migraine brain are revealed by advanced magnetic resonance imaging techniques, and attempts to detect the visualization markers of this disease progressively increase. This overview article aims to summarize the results of recent studies that reflect achievements in understanding the pathophysiology of migraine, as well as the possibility of using neuroimaging techniques in diagnosing migraines.
30
Ostashko, M. P., and T. I. Nasonova. "MARKERS OF NEUROVISULATION IN MIGRAINE DIAGNOSTICS." PRECARPATHIAN BULLETIN OF THE SHEVCHENKO SCIENTIFIC SOCIETY Pulse, no. 5(57) (April 24, 2019): 108–13. http://dx.doi.org/10.21802/2304-7437-2019-5(57)-108-113.
Full textAbstract:
In clinical medicine, the diagnosis of migraine is based on anamnesis and symptoms, and instrumental diagnostic methods are considered non-informative. Numerous studies of the brain, during headaches and between them, have made a significant contribution to understanding the pathophysiology of migraines. Structural and functional changes in the migraine brain are revealed by advanced magnetic resonance imaging techniques, and attempts to detect the visualization markers of this disease progressively increase. This overview article aims to summarize the results of recent studies that reflect achievements in understanding the pathophysiology of migraine, as well as the possibility of using neuroimaging techniques in diagnosing migraines.
31
Fialho, Libânia Melo Nunes, Ricardo Silva Pinho, Jaime Lin, Thais Soares Cianciarullo Minett, Maria Sylvia de Souza Vitalle, Mauro Fisberg, Mario Fernando Prieto Peres, Luiz Celso Pereira Vilanova, and Marcelo Rodrigues Masruha. "Sleep terrors antecedent is common in adolescents with migraine." Arquivos de Neuro-Psiquiatria 71, no. 2 (January 11, 2013): 83–86. http://dx.doi.org/10.1590/s0004-282x2013005000006.
Full textAbstract:
Migraines and sleep terrors (STs) are highly prevalent disorders with striking similarities. The aim of this study was to evaluate the effect of the antecedent of STs by comparing adolescents suffering from migraines with healthy controls in a large consecutive series. METHODS: All patients were subjected to a detailed headache questionnaire and were instructed to keep a headache diary during a two-month period. The age range was 10 to 19 years. The diagnosis of STs was defined according to the International Classification of Sleep Disorders. RESULTS: A total of 158 participants were evaluated. Of these participants, 50 suffered from episodic migraines (EMs), 57 had chronic migraines (CMs) and 51 were control subjects (CG). Participants who had a history of STs had significantly more migraines than participants who did not. CONCLUSIONS: Migraine is strongly associated with a history of STs in the adolescent population independent of demographics and pain intensity.
32
Kim, Seung, Kyu-Tae Han, Suk-Yong Jang, Ki-Bong Yoo, and Sun Kim. "The Association between Migraine and Types of Sleep Disorder." International Journal of Environmental Research and Public Health 15, no. 12 (November 26, 2018): 2648. http://dx.doi.org/10.3390/ijerph15122648.
Full textAbstract:
Background: Migraines gradually increase year by year, as does its burden. Management and prevention are needed to reduce such burdens. Previous studies have suggested that daily health behaviors can cause migraines. Sleep is a substantial part of daily life, and in South Korea, the average sleep duration is shorter than in other countries. Thus, this study focused on the increase of both diseases, and analyzed sleep disorders as a risk factor for migraines. Methods: The data used in this study was that of the national health insurance service (NHIS) national sample cohort. We used a matched cohort study design that matched non-patients based on patients with sleep disorders, and included 133,262 patients during 2012–2015. We carried out a survival analysis using a Cox proportional hazard model with time-dependent covariates to identify the association between migraines and sleep disorders. Results: Approximately 11.72% of patients were diagnosed with migraines. Sleep disorders were positively correlated with the diagnosis of migraine (Hazard Ratio, 1.591; p < 0.0001). By the types of sleep disorder, patients who were diagnosed as having insomnia, rather than other types of sleep disorder, had the greatest associations with migraine. The associations were greater for males, people with lower income, the elderly population, and patients with mild comorbid conditions. Conclusion: This study provides evidence that migraine is associated with sleep disorders, especially insomnia. Based on these findings, healthcare professionals and policy makers have to reconsider the present level of insurance coverage for sleep medicine, recognize the risk of sleep-related diseases and educate patients about the need for appropriate care.
33
Karr, J. E., B. A. Maxwell, R. Zafonte, P. D. Berkner, and G. L. Iverson. "Differences in Symptom Clusters at Baseline Testing among Student Athletes with ADHD or Migraines." Archives of Clinical Neuropsychology 34, no. 5 (July 2019): 751. http://dx.doi.org/10.1093/arclin/acz026.21.
Full textAbstract:
Abstract Purpose This study was designed to determine whether the factor structure of the Post-Concussion Symptom Scale (PCSS) is consistent (i.e., invariant) in subgroups of youth with pre-existing attention-deficit/hyperactivity disorder (ADHD) or migraines. A four-factor model of the PCSS has empirical support (i.e., cognitive-sensory, sleep-arousal, vestibular-somatic, and affective symptoms), and the current investigation examined (i) whether this model is invariant across athletes with and without ADHD or migraines and (ii) group differences across symptom clusters. Methods Participants included a large sample of adolescent athletes (N=39,242; 54.4% boys; 13–18 years-old, M=15.50±1.27 years), among which 2,543 reported ADHD and 2,638 reported having migraines. The 22-item PCSS was administered at pre-season baseline. Statistical analyses included invariance testing across ADHD and migraine groups. Good fit was defined as CFI≥0.95. Effect sizes for group differences in symptom clusters were calculated. Results Configural invariance was established across participants with and without ADHD (CFI=0.967) and with and without migraines (CFI=0.965); however, weak invariance was not established for either diagnostic group. Effect sizes (Cohen’s d) of group differences varied by symptom cluster: cognitive-sensory (ADHD=0.44; migraine=0.38), sleep-arousal (0.33, 0.37), vestibular-somatic (0.17, 0.45), and affective (0.27, 0.28). Conclusion Although the four-factor model has been previously published and replicated among healthy student athletes, this model was only partially invariant for participants with ADHD or migraines. The cognitive-sensory factor showed the largest differences based on ADHD, whereas the vestibular-somatic factor showed the largest differences based on migraine history.
34
Fuh, Jong-Ling, Ming-Yi Chung, Shu-Chih Yao, Ping-Kun Chen, Yi-Chu Liao, Chia-Lin Hsu, Po-Jen Wang, et al. "Susceptible genes of restless legs syndrome in migraine." Cephalalgia 36, no. 11 (July 19, 2016): 1028–37. http://dx.doi.org/10.1177/0333102415620907.
Full textAbstract:
Objective Several genetic variants have been found to increase the risk of restless legs syndrome (RLS). The aim of the present study was to determine if these genetic variants were also associated with the comorbidity of RLS and migraine in patients. Methods Thirteen single-nucleotide polymorphisms (SNPs) at six RLS risk loci ( MEIS1, BTBD9, MAP2K5, PTPRD, TOX3, and an intergenic region on chromosome 2p14) were genotyped in 211 migraine patients with RLS and 781 migraine patients without RLS. Association analyses were performed for the overall cohort, as well as for the subgroups of patients who experienced migraines with and without aura and episodic migraines (EMs) vs. chronic migraines (CMs). In order to verify which genetic markers were potentially related to the incidence of RLS in migraine patients, multivariate regression analyses were also performed. Results Among the six tested loci, only MEIS1 was significantly associated with RLS. The most significant SNP of MEIS1, rs2300478, increased the risk of RLS by 1.42-fold in the overall cohort ( p = 0.0047). In the subgroup analyses, MEIS1 augmented the risk of RLS only in the patients who experienced EMs (odds ratio (OR) = 1.99, p = 0.0004) and not those experiencing CMs. Multivariate regression analyses further showed that rs2300478 in MEIS1 (OR = 1.39, p = 0.018), a CM diagnosis (OR = 1.52, p = 0.022), and depression (OR = 1.86, p = 0.005) were independent predictors of RLS in migraine. Conclusions MEIS1 variants were associated with an increased risk of RLS in migraine patients. It is possible that an imbalance in iron homeostasis and the dopaminergic system may represent a link between RLS incidence and migraines.
35
Liu, Huanxian, Lu Wang, Chunfu Chen, Zhao Dong, and Shengyuan Yu. "Association between Dietary Niacin Intake and Migraine among American Adults: National Health and Nutrition Examination Survey." Nutrients 14, no. 15 (July 25, 2022): 3052. http://dx.doi.org/10.3390/nu14153052.
Full textAbstract:
Migraine is related to brain energy deficiency. Niacin is a required coenzyme in mitochondrial energy metabolism. However, the relationship between dietary niacin and migraines remains uncertain. We aimed to evaluate the relationship between dietary niacin and migraine. This study used cross-sectional data from people over 20 years old who took part in the National Health and Nutrition Examination Survey between 1999 and 2004, collecting details on their severe headaches or migraines, dietary niacin intake, and several other essential variables. There were 10,246 participants, with 20.1% (2064/10,246) who experienced migraines. Compared with individuals with lower niacin consumption Q1 (≤12.3 mg/day), the adjusted OR values for dietary niacin intake and migraine in Q2 (12.4–18.3 mg/day), Q3 (18.4–26.2 mg/day), and Q4 (≥26.3 mg/day) were 0.83 (95% CI: 0.72–0.97, p = 0.019), 0.74 (95% CI: 0.63–0.87, p < 0.001), and 0.72 (95% CI: 0.58–0.88, p = 0.001), respectively. The association between dietary niacin intake and migraine exhibited an L-shaped curve (nonlinear, p = 0.011). The OR of developing migraine was 0.975 (95% CI: 0.956–0.994, p = 0.011) in participants with niacin intake < 21.0 mg/day. The link between dietary niacin intake and migraine in US adults is L-shaped, with an inflection point of roughly 21.0 mg/day.
36
Kang, Ho Suk, So Young Kim, Ji Hee Kim, Eun Soo Kim, Hyo Geun Choi, Hyun Lim, Joo-Hee Kim, et al. "Association between Migraines and Prior Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort." Pharmaceuticals 15, no. 11 (November 10, 2022): 1385. http://dx.doi.org/10.3390/ph15111385.
Full textAbstract:
The effect of proton pump inhibitor (PPI) use on migraine risk remains controversial. We explored the odds of migraines in relation to prior PPI use and treatment duration. Data from the Korean National Health Insurance Service-Health Screening Cohort (2002–2015) were analyzed in this nested case-control study involving 28,159 participants with incident migraines and 112,636 controls (1:4 matched by sex, age, income, and residential region). The baseline covariates were balanced by performing propensity score overlap weighting-based adjustments, and the effect of prior PPI use (past vs. current) and treatment duration (<30 and 30–365 days vs. ≥365 days) on incident migraines was evaluated using logistic regression. In past and current PPI users, prior PPI use raised the likelihood of migraines (adjusted odds ratio [95% confidence interval]: 2.56 [2.36–2.79] and 4.66 [4.29–5.06], respectively). Participants who used PPI for <30, 30–365, or ≥365 days exhibited high odds of migraines (2.49 [2.29–2.72], 4.41 [4.05–4.79], and 4.14 [3.77–4.54], respectively). Incident migraines with or without aura also increased independently of PPI use history or duration. In summary, prior PPI use, irrespective of the elapsed time since use and the duration of use, is possibly associated with incident migraines with or without aura.
37
Mirza, Babar, and Wageha Akel. "Current Opinion in Pharmacological and Non-Pharmacological Treatment of Migraine: A Focus on Calcitonin Gene-Related Peptide." Neuro – Open Journal 8, no. 1 (December 31, 2021): 5–10. http://dx.doi.org/10.17140/noj-8-136.
Full textAbstract:
The most common neurologic disorder is migraines. Migraine is defined as throbbing headaches that can be associated with auras. The headaches are episodic and can be debilitating in quality. Migraines can be triggered by emotional stress, lack of sleep, bright lights, loud noise, certain foods, and other environmental factors. The most effective way of preventing migraines is to avoid these triggers. A migraine can begin with prodromes or warning signs such as loss of vision, loss of motor reflexes or sensation. In this review, the types of migraine, signs and symptoms, pathways leading up to auras, and detailed pathophysiology will be discussed. The pathophysiology of a migraine consists of three different mechanisms: 1) cortical spreading depression, 2) the trigemino vascular system, and 3) sensitization. Three different treatment methods for a migraine will be discussed: 1) pharmacological, 2) non-pharmacological and 3) lifestyle modifications. Lifestyle modifications include eating a healthy diet, exercising, and maintaining proper sleep hygiene. Pharmacological treatments can be preventative or abortive. The latest migraine treatment of calcitonin gene-related peptide (CGRP) antagonist use will be discussed in this review and compared to other treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and Triptans. Future research methods to prevent and better treat migraine headaches are considered a hot topic in medicine and these novel methods will be discussed.
38
Baker, B. J., A. Curtis, P. Trueblood, and E. Vangsnes. "Vestibular functioning and migraine: comparing those with and without vertigo to a normal population." Journal of Laryngology & Otology 127, no. 12 (October 22, 2013): 1169–76. http://dx.doi.org/10.1017/s0022215113002302.
Full textAbstract:
AbstractObjective:This study compared vestibular functioning in a migrainous vertigo group, a migraine without vertigo group and a control group. It was hypothesised that the migrainous vertigo group would perform worse in tests of vestibular function and gait than the other groups during a non-migrainous period.Methods:Sixty-six participants (22 per group) were assessed using the head shake sensory organisation test, the gaze stabilisation test, the dynamic visual acuity test and the functional gait assessment. Separate analyses of variance and planned pair-wise comparisons (alpha = 0.05) were performed.Results:There was a difference between the results of the non-migraine group and the two migraine groups for the gaze stabilisation pitch test (p < 0.003), in which the control group showed faster head movement. There were also group differences in functional gait (p < 0.0001); the control group scored highest and the migrainous vertigo group scored lowest. There were no differences in the vestibular spinal reflex and balance tests.Conclusion:These findings indicate underlying differences in the vestibular ocular reflexes and function of migraine sufferers compared with those who do not suffer migraines, but the difference is most pronounced for those with migrainous vertigo. This suggests that vestibular rehabilitation for migrainous vertigo should focus on vestibular ocular reflexes and functional retraining.
39
Younis, Ali, Yahya Qasem, and Ali Neamat Sulaiman Alallaf. "The Frequency of Fibromyalgia in Migraine Patients." Open Access Macedonian Journal of Medical Sciences 10, B (January 25, 2022): 260–64. http://dx.doi.org/10.3889/oamjms.2022.8246.
Full textAbstract:
BACKGROUND: Fibromyalgia (FM) is a prevailing debilitating ailment that has been described in patients with migraines in several investigations. AIM: The study aimed to investigate the frequency of FM in migraine patients and to study the characteristics of migraine patients with comorbid FM. METHODS: This case–control study was piloted in the Neurology Unit, Department of Medicine in Ibn Sina Teaching Hospital in Mosul, Iraq, between March and November 2020. One hundred consecutive patients with migraine and 100 healthy controls were included in this study. The sociodemographic and headache characteristics of the patients were recorded. RESULTS: The frequency of FM was statistically higher among participants with migraines (27%) when compared to the controls (5%). Migraine patients with FM had a substantially older mean age and a higher ratio of female gender than migraine patients without FM. FM was found to be more common in patients without versus with aura. Patients with comorbid FM had greater headache frequency (p = 0.0002), headache intensity (p = 0.007), and higher scores on the “Headache Impact Test (HIT-6)” (p = 0.0001). CONCLUSIONS: There is a high frequency of FM in patients with migraines. Patients with coexistent “FM” and “migraine” tended to have more depressive symptoms, greater headache intensity, headache frequency, and when compared to healthy people, they are more likely to have a significant headache-related disability.
40
Beiraghi Toosi, Mehran, Alireza Ghodsi, Mehrdad Sarabi, Sara Ghahremani, Nasrin Fazeli, and Somayeh Ghahremani. "Investigating the Frequency of Infantile Colic in Children with Migraine." Journal of Child Science 11, no. 01 (January 2021): e89-e92. http://dx.doi.org/10.1055/s-0041-1728729.
Full textAbstract:
AbstractInfantile colic is a common problem observed within the first 3 months of life in infants and is a common cause of crying among infants. Migraine is a common cause of recurrent primary headaches during childhood. The pathogenesis of migraine and colic has remained unknown, but various factors seem to be involved. Patients with migraine may have a medical history of infantile colic, and infantile colic is considered an early manifestation of migraine. In this study, we investigate the frequency of history of infantile colic in 6- to 14-year-old children with migraines. In this case–control study, 80 children with the diagnosis of migraine and 100 children without migraine, all within the age range of 6 to 14 years, were included. A checklist was completed for each person about the background information and history of infantile colic as well as the history of migraine in parents. Among the children with migraine, 92.5%, and in the control group, 10%, had a familial history of migraine. Also, among the children with migraine, 61.25%, and in the control group, 4%, had a history of infantile colic. The obtained results showed that the frequency of a history of infantile colic was significantly higher in the case group than in the control group. This study provides some evidence regarding the presence of association between infantile colic as well as the familial history of migraines and developing migraines in the future. However, due to some limitations of the retrospective manner of the study, the results should be completed with future studies.
41
Thanh, Chu Duc, Chu Van Men, Hyung-Min Kim, and Jong-Seong Kang. "Network Pharmacology-Based Investigation on Therapeutic Mechanisms of the Angelica dahurica Radix and Ligusticum chuanxiong Rhizoma Herb Pair for Anti-Migraine Effect." Plants 11, no. 17 (August 24, 2022): 2196. http://dx.doi.org/10.3390/plants11172196.
Full textAbstract:
Migraines are a common neurological disorder characterized by desperate throbbing unilateral headaches and are related to phonophobia, photophobia, nausea, and vomiting. The Angelica dahurica Radix and Ligusticum chuanxiong Rhizoma herb pair (ALHP) has been used to treat migraines for centuries in traditional Chinese medicine (TCM). However, the physiological mechanisms of migraine treatment have not yet been elucidated. In this study, a total of 50 hub targets related to the effect of 28 bioactive compounds in ALHP on anti-migraine were obtained through network pharmacology analysis. GO and KEGG analyses of the hub targets demonstrated that ALHP treatment of migraines significantly involved the G-protein-coupled receptor signaling pathway, chemical synaptic transmission, inflammatory response, and other biological processes. According to the degree of gene targets in the network, ACE, SLC3A6, NR3CI, MAPK1, PTGS2, PIK3CA, RELA, GRIN1, GRM5, IL1B, and DRD2 were found to be the core gene targets. The docking results showed a high affinity for docked conformations between compounds and predicted targets. The results of this study suggest that ALHP could treat migraines by regulating immunological functions, diminishing inflammation, and improving immunity through different physiological pathways, which contributes to the scientific base for more in-depth research as well as for a more widespread clinical application of ALHP.
42
Didriksen, Maria, Thomas F. Hansen, Lise W. Thørner, Kristoffer S. Burgdorf, Christian Erikstrup, Ole B. Pedersen, Helene M. Paarup, et al. "Restless legs syndrome is associated with increased risk of migraine." Cephalalgia Reports 1 (January 1, 2018): 251581631878074. http://dx.doi.org/10.1177/2515816318780743.
Full textAbstract:
Migraine and restless legs syndrome (RLS) are common disorders that are associated with a high level of individual suffering and major comorbidities. The aetiologies of the disorders are largely unknown, although both migraine and RLS have been linked to disturbances in the dopaminergic system and sleep issues, suggesting a relationship between the disorders. This study examines the association between RLS and migraine in a large population of otherwise healthy adults who are not taking medication. Cross-sectional study that included 20,938 participants enrolled in the Danish Blood Donor Study from 1 May 2015 to 1 February 2017. The study included complete information on migraines, the Cambridge-Hopkins RLS questionnaire, the Major Depression Inventory Scale, sex, age, body mass index (BMI), educational level, smoking status and alcohol consumption. Associations between RLS and migraine, with and without aura, were examined using multivariable logistic regression analysis. Among the participants, 4827 were self-reported migraine sufferers and 1091 were classified as suffering from RLS. Individuals with RLS had an increased risk of migraine compared to non-RLS sufferers, with an odds ratio (OR) = 1.52 (95% confidence interval: 1.33–1.73). For the investigated subtypes of migraine, this association was found to be OR = 1.55 (1.31–1.83) for migraines with aura and OR = 1.29 (1.09–1.52) for migraines without aura. We found a significantly increased occurrence of migraine in individuals with RLS. This risk was independent of sex, age, BMI, educational level, smoking status, alcohol consumption and depressive disorder. Our findings suggest that RLS and migraine may have a common aetiology.
43
Woldeamanuel, Yohannes W., Corinne Cooley, Katharine Foley-Saldena, and Robert P. Cowan. "Migraine and Complex Regional Pain Syndrome: A Case-Referent Clinical Study." BioMed Research International 2017 (2017): 1–8. http://dx.doi.org/10.1155/2017/5714673.
Full textAbstract:
We studied clinical phenotype differences between migraineurs with CRPS (Mig + CRPS) and those without (Mig − CRPS). Mig + CRPS cases and Mig − CRPS referents aged ≥18 years were enrolled. Diagnosis was made in accordance with International Classification of Headache Disorders-3 beta (ICHD-3 beta) for migraine and Budapest Criteria for CRPS. Migraines both with and without aura were included. A total of 70 Mig + CRPS cases (13% males, mean age 48 years) and 80 Mig − CRPS referents (17% males, mean age 51 years) were included. 33% of Mig + CRPS and 38% of Mig − CRPS exhibited episodic migraine (EM) while 66% of Mig + CRPS and 62% of Mig − CRPS had chronic migraine (CM) (OR = 0.98, CI 0.36, 2.67). Median duration of CRPS was 3 years among EM + CRPS and 6 years among CM + CRPS cohort (p<0.02). Mig + CRPS (57%) carried higher psychological and medical comorbidities compared to Mig − CRPS (6%) (OR 16.7, CI 10.2, 23.6). Higher migraine frequency was associated with longer CRPS duration. Migraineurs who developed CRPS had higher prevalence of psychological and medical disorders. Alleviating migraineurs’ psychological and medical comorbidities may help lower CRPS occurrence.
44
Bach, Linda Lu, and Joshana Goga. "Management of migraine headaches in a chronic pain patient: A case report." Mental Health Clinician 6, no. 3 (January 1, 2016): 154–58. http://dx.doi.org/10.9740/mhc.2016.05.154.
Full textAbstract:
Abstract Managing migraines complicated with medication overuse headaches and opioid-induced hyperalgesia can be challenging, especially within the geriatric and chronic pain population. A 65-year-old woman with a degenerative spine condition and chronic migraine headaches, along with other comorbidities, was admitted to the geriatric psychiatry unit for extreme mood swings and paranoia. Prior to admission, she had been taking extended-release morphine sulfate twice daily for more than a month and was unable to determine triggers to her frequent migraine headaches. She had a history of medication overuse and severe migraine episodes within 4 weeks prior to admission. This case report reviews the challenges of treating a geriatric patient with probable chronic migraines in addition to other pain conditions and comorbidities.
45
Connelly, Mark, Jennifer Bickel, Tammie Wingert, and Cynthia Galemore. "The Headache Action Plan Project for Youth (HAPPY): School Nurses as Facilitators of System Change in Pediatric Migraine Care." NASN School Nurse 33, no. 1 (August 4, 2017): 40–47. http://dx.doi.org/10.1177/1942602x17719300.
Full textAbstract:
Migraine is a common health problem in youth that is ranked highest for disability among neurological conditions and is one of the leading reasons for school absences. Children with migraines frequently are seen by the school nurse for care, sometimes before ever being seen by another healthcare provider for evaluation and treatment. As such, school nurses have the unique opportunity to provide education and resources to children with migraines and their family. This article provides information on the Headache Action Plan Program for Youth (HAPPY), a project involving the provision of live and online migraine education and management resources to school nurses, children, families, and primary care providers in an effort to improve migraine recognition and care in the community.
46
Rajalekshmi K, Dhanya Dharman, Deepa Manohar, Shaiju S Dharan, Dhanya S S, and Bismi S. "A survey on functioning of male and female with migraine." International Journal of Research in Hospital and Clinical Pharmacy 1, no. 3 (August 1, 2019): 85–87. http://dx.doi.org/10.33974/ijrhcp.v1i3.127.
Full textAbstract:
Migraines are severe, recurring, and painful headaches. The extreme pain have that migraines cause can last for hours or even days. Migraines can follow an aura of sensory disturbances followed by a severe headache that often appears on one side of the head. Objective of the study include; To find out whether male and female are more prone to develop migraine, To evaluate which triggering factors contributes to migraine and To evaluate the people taking OTC for migraine. A Prospective survey will be carried out in 75 peoples using the information’s gathered from students in Pharmacy colleges in Trivandrum. This study provides the prevalence of migraine headache. Past history, medication usage, diagnosis, treatment, triggering factors, physical and intellectual activities was collected, analysed properly and response is recorded. These collected data will be subjected to statistical analysis. In the current research, a survey on functioning of male and female with migraine was formulated. Among the respondents about 18-35 age group is commonly affected migraine with 98.7%(n=74). Approximately, 63.5%(n=47) female are affected with migraine than 36.5%(n=27) male. About 11.16%(n=8) of patients taken prescription drugs and 52.2%(n=48) are taken over-the-counter medicines. Migraine worsened in 77.20%(n=48) patients with stress, 50%(n=33) bright sunshine, 33.30%(n=22) loud noise and others have air travel, fatigue, certain smells and perfume. The goal of management is to reduce frequency and severity of episodes in males and females. Also limit the impact of this chronic pain condition.
47
Piejko, L. "Physiotherapeutic interventions in patients with migraines." Physiotherapy and Health Activity 25, no. 1 (March 1, 2018): 21–25. http://dx.doi.org/10.1515/pha-2017-0004.
Full textAbstract:
Abstract Migraine headaches represent one of the most frequent chronic problems which significantly impact on the limitation of everyday human functioning. Despite pharmacological treatment, many people also need preventive care to reduce intensity of the symptoms of the disease, reduce frequency of migraine attack and to enhance the response to the abortive treatment. New strategies of combining pharmacological and non-pharmacological treatment have been demonstrated to be as effective as taking modern medicines. Unfortunately, the awareness of availability and effectiveness of non-pharmacological methods to treat migraines remains to be insufficient. Therefore, the need arises for educating medical staffs and patients and continuation of the research in this field of science. The study presents a brief characterization of the disease, discusses non-pharmacological methods to treat migraines and proposes the guidelines for physiotherapists to be used in the clinical practice.
48
Qin, Tong, and Chunfu Chen. "Cognitive Dysfunction in Migraineurs." Medicina 58, no. 7 (June 29, 2022): 870. http://dx.doi.org/10.3390/medicina58070870.
Full textAbstract:
Background and Objectives: Migraines are one of the most common types of primary headaches in neurology. Many studies to date have investigated cognitive impairment in migraineurs, but the results are inconsistent. This study aimed to investigate the cognitive function of migraineurs and explore the influencing factors. Material and Methods: A total of 117 patients with primary headaches (87 with migraine and 30 with tension-type headache (TTH)) and 30 healthy controls were enrolled. General information and data on headache clinical characteristics, and assessments of headache-related disability, psychological symptoms, and cognitive function were collected for statistical analysis. Results: The Montreal Cognitive Assessment (MoCA) total score and the scores of visuospatial and executive functions, language, and delayed recall in the migraine and TTH groups were significantly lower than those in the healthy control group (all p < 0.05). The MoCA total score did not correlate with Headache impact test-6, Migraine Disability Assessment Questionnaire, Patient Health Questionnaire-9, or Generalized Anxiety Disorder Questionnaire-7 scores in migraineurs (all p > 0.0125). The multiple linear regression analysis showed that age and duration of attack had a major influence on the overall and various fields of cognition in migraineurs. Conclusion: The study confirmed the impairment of cognitive function in patients with migraine and TTH, and found that the duration of attack had an effect on cognitive function in migraineurs.
49
Pinkerman, Brenda, and Kenneth Holroyd. "Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine." Cephalalgia 30, no. 10 (March 31, 2010): 1187–94. http://dx.doi.org/10.1177/0333102409359315.
Full textAbstract:
Introduction: We compared migraine features and acute therapy response in menstrually-related migraines (MRMs) and non-menstrually-related migraines (NMRMs). Methods: Women with frequent, disabling migraines were prospectively diagnosed with MRM according to the International Classification of Headache Disorders (ICHD-II; N = 107) criteria using a daily electronic headache dairy. Participants received individualized acute therapy while free of prophylactic migraine medications. Results: Repeated measures logistic regression revealed MRMs were longer (23.4 vs. 16.1 hours, odds ratio [OR] = 1.01, confidence interval [CI] 1.01, 1.02) and more likely associated with disability (85.6% vs. 75.6%, OR = 1.82, CI 1.27, 2.58) than NMRMs. MRMs were also less responsive to acute therapy (two-hour pain-free response = 6.7% vs. 13.4%, OR = .45, CI .26, .80) and reoccurred more frequently within 24 hours after a four-hour pain-free response (36.0% vs. 19.6%, OR = 2.12, CI 1.27, 3.53) than NMRMs. Discussion: These results support the proposed ICHD-II classification of MRMs and suggest that MRMs may require a treatment approach different from that for NMRMs.
50
Allais, Gianni, Ilaria Castagnoli Gabellari, Ornella Mana, and Chiara Benedetto. "Treatment Strategies for Menstrually Related Migraine." Women's Health 8, no. 5 (September 2012): 529–41. http://dx.doi.org/10.2217/whe.12.37.
Full textAbstract:
Approximately 50% of migrainous women suffer from menstrually related migraine (MRM), a type of migraine in which the attacks occur at the same time as or near the menstrual flow. Attacks of MRM tend to be longer, more intense and disabling and sometimes less responsive to treatment than non-menstrual migraines. Similar to the management of non-menstrual migraine, the use of triptans and NSAIDs is the gold standard for MRM treatment. In this paper, the most important studies in the literature that report the effectiveness of triptans, of certain associated drugs and other analgesic agents are summarized. Preventive strategies that can be used if a prophylactic treatment is needed is also analyzed, with particular attention paid to the use of perimenstrual prophylaxis with triptans and/or NSAIDs. Moreover, considering the peculiar interaction between menstrual migraine and female sex hormones, brief mention is made to possible hormonal manipulations.